Scotland says yes to Shire's Elvanse but no to Pfizer's Xalkori
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium, Scotland's health technology appraisal body, has okayed Shire's attention deficit/hyperactivity disorder (ADHD) drug Elvanse/Vyvanse (lisdexamfetamine dimesylate) for use on the Scottish National Health Service. However, Pfizer's lung cancer Xalkori (crizotinib) failed to make the grade.